ArticleFrontiers in aging neuroscience2019
A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD.
Article in Frontiers in aging neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 45 citations in OpenAlex.
- A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment.GeroScience · 2024Trial
- NAD⁺ biology and supplementation: From mechanisms to clinical perspectives.Molecular biology reports · 2026Review
- Effects and Mechanisms of NAD + on Lung Injury After Cardiac Arrest and Cardiopulmonary Resuscitation in Swine.Shock (Augusta, Ga.) · 2026Article
- Synaptic aging and neurodegeneration: the role of synaptic vesicle dynamics and neurotransmitter imbalance.Biogerontology · 2026Review
- Narrative review of intravenous NADFrontiers in aging · 2026Review
- Intravenous infusion of nicotinamide adenine dinucleotide (NADFrontiers in aging · 2026Article
- NADNature metabolism · 2025Review
- The role of NADnpj metabolic health and disease · 2025Review
- NADSub-cellular biochemistry · 2024Review
- Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns.Endocrine reviews · 2023Review
- The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update.Advances in nutrition (Bethesda, Md.) · 2023Review
- Nicotinamide Riboside, a Promising Vitamin BMolecules (Basel, Switzerland) · 2023Review
- Ex Vivo Transdermal Delivery of Nicotinamide Mononucleotide Using Polyvinyl Alcohol Microneedles.Polymers · 2023Article
- Optimized protocol for quantification of extracellular nicotinamide adenine dinucleotide: evaluating clinical parameters and pre-analytical factors for translational research.Frontiers in medicine · 2023Article
- Article
- Supplementation with NADNutrients · 2022Review
- NADMetabolites · 2022Review
- NAXE deficiency: A neurometabolic disorder of NAD(P)HX repair amenable for metabolic correction.Molecular genetics and metabolism · 2022Review
- Differences in Extracellular NADBiology · 2022Article
- Recent Neurotherapeutic Strategies to Promote Healthy Brain Aging: Are we there yet?Aging and disease · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence suggests that active maintenance of optimal levels of the essential pyridine nucleotide, nicotinamide adenine dinucleotide (NAD+) is beneficial in conditions of either increased NAD+ turnover or inadequate synthesis, including Alzheimer's disease and other neurodegenerative disorders and the aging process. While studies have documented the efficacy of some NAD+ precursors such as nicotinamide riboside (NR) in raising plasma NAD+, no data are currently available on the fate of directly infused NAD+ in a human cohort. This study, therefore, documented changes in plasma and urine levels of NAD+ and its metabolites during and after a 6 h 3 μmol/min NAD+ intravenous (IV) infusion. Surprisingly, no change in plasma (NAD+) or metabolites [nicotinamide, methylnicotinamide, adenosine phosphoribose ribose (ADPR) and nicotinamide mononucleotide (NMN)] were observed until after 2 h. Increased urinary excretion of methylnicotinamide and NAD+ were detected at 6 h, however, no significant rise in urinary nicotinamide was observed. This study revealed for the first time that: (i) at an infusion rate of 3 μmol/min NAD+ is rapidly and completely removed from the plasma for at least the first 2 h; (ii) the profile of metabolites is consistent with NAD+ glycohydrolase and NAD+ pyrophosphatase activity; and (iii) urinary excretion products arising from an NAD+ infusion include NAD+ itself and methyl nicotinamide (meNAM) but not NAM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.